A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. - Heidenreich R; Jasny E; Kowalczyk A; Lutz J; Probst J; Baumhof P; Scheel B; Voss S; Kallen KJ; Fotin-Mleczek M (International journal of cancer, 2015)